Latest ROE for SHL Telemedicine: -100.28% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow-100.28%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
SHL Telemedicine (SHLT) currently reports a ROE of -100.28%. That is above the Healthcare sector average of -100.59%. Use the charts on this page to explore SHL Telemedicine's ROE history and peer comparisons.
SHL Telemedicine's ROE of -100.28% is higher than the Healthcare sector average of -100.59%. That is roughly 0.3% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but SHL Telemedicine's current -100.28% should be judged against Healthcare norms (sector average: -100.59%) and against SHLT's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of -100.28%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is -100.59%. From there, open related valuation or income-statement pages for SHL Telemedicine, and consider following SHLT for alerts when major investors trade the stock.
SHL Telemedicine is classified in the Healthcare sector. On ROE, it currently shows -100.28% versus a sector average near -100.59%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing SHLT with unrelated industries.